Moreover, the high co‐expression level of SLC7A11‐GPX4 mayt be a significant independent prognostic factor of poor prognosis and a potential therapeutic target for platinum resistance in patients with ovarian cancer. This evidence concerns the gene SLC7A11 and ovarian carcinoma.